Chester County News and Community Website
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar® Advanced Therapy for Mental Health than with TMS treatments that claim deeper …
Read More
MALVERN, PA — Vishay Intertechnology, Inc. (NYSE: VSH) announced this week that it has enhanced the Vishay Draloric RCC1206 e3 thick film chip resistor in the 1206 case size with …
Read More
ELVERSON, PA — Revivalist Spirits, an innovative craft distillery which has been producing a variety of seasonally-focused botanical gins in historic Chester County outside of Philadelphia since 2016, has been …
Read More
WASHINGTON, D.C. — Secretary of Commerce Gina Raimondo and National Economic Council Director Brian Deese on Thursday convened semiconductor industry participants and discussed the progress industry has made to address …
Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar® Advanced Therapy for Mental Health than with TMS treatments that claim deeper …
Read More MALVERN, PA — Vishay Intertechnology, Inc. (NYSE: VSH) recently introduced a new series of AEC-Q200 qualified, high power thin film wraparound chip resistors.
Read More
WAYNE, PA — PACE Solutions and Xemplar Insights have partnered to provide an integrated solution for P&C insurers and MGAs. This partnership allows mutual customers of PACE and Xemplar to …
Read More MALVERN, PA — Vishay Intertechnology, Inc. (NYSE: VSH) this week introduced the industry’s first Automotive Grade IHLP® low profile, high current inductor in the 19 mm by 19 mm by …
Read More
MALVERN, PA — Rajant Corporation this week announced two new products at MINExpo. The latest enhancement adds a global LTE radio to its fourth-generation industry-leading BreadCrumb® Peregrine product line. With …
Read More
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center, efficacy and safety (RECONNECT) Phase 3 trial.
Read More